Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.44 |
| ▸ | GCK | P35557 | 2/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24660367 | 0.90 | KMT2A (0.54) | KMT2AEPHX2POLBGAA | |
| SCHEMBL7872045 | 0.88 | HCAR3 (0.51) | KMT2AEPHX2HCAR3GCKRARA | |
| SCHEMBL10015137 | 0.88 | KMT2A (0.49) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL3562349 | 0.83 | KMT2A (0.44) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL178731 | 0.82 | KMT2A (0.57) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL13349297 | 0.82 | KMT2A (0.50) | KMT2AEPHX2POLB | |
| SCHEMBL29679239 | 0.80 | KMT2A (0.51) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL12235815 | 0.78 | KMT2A (0.64) | KMT2AEPHX2FABP7FABP5MDM4 | |
| SCHEMBL13187755 | 0.77 | EPHX2 (0.60) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL3757636 | 0.75 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396527-B2 | Dual mass spectrometry-cleavable crosslinking reagents for protein-protein interactions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-26 | — | — | US | disclosed |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
| US-20200354403-A1 | DUAL MASS SPECTOMETRY-CLEAVABLE CROSSLINKING REAGENTS FOR PROTEIN-PROTEIN INTERACTIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-12 | — | — | US | disclosed |
| US-10752655-B2 | Dual mass spectrometry-cleavable crosslinking reagents for protein-protein interactions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-25 | — | — | US | disclosed |
| US-20180346505-A1 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | SOLSTICE BIOLOGICS LTD (IE) | 2018-12-06 | — | — | US | disclosed |
| EP-3229815-A2 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | Solstice Biologics, Ltd. (IE) | 2017-10-18 | — | — | EP | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3152308-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | Solstice Biologics, Ltd. (IE) | 2017-04-12 | — | — | EP | disclosed |
| EP-3066105-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | Solstice Biologics, Ltd. (IE) | 2016-09-14 | — | — | EP | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
| US-20120014972-A1 | INFLUENZA VIRUS COMPOSITIONS AND METHODS FOR UNIVERSAL VACCINES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-01-19 | — | — | US | disclosed |
| US-20120014972-A1 | INFLUENZA VIRUS COMPOSITIONS AND METHODS FOR UNIVERSAL VACCINES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-01-19 | — | — | US | disclosed |
| WO-2011094363-A2 | INFLUENZA VIRUS COMPOSITIONS AND METHODS FOR UNIVERSAL VACCINES | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-08-04 | — | — | WO | disclosed |
| EP-1934251-B1 | INTERLEUKIN-8 LABELLED VIA ONE OR MORE SITE SPECIFICALLY CONJUGATED HYDRAZINONICOTINAMIDE (HYNIC) MOIETIES AND ITS USE IN DIAGNOSIS OF INFECTION AND INFLAMMATION | STICHTING KATHOLIEKE UNIV (NL) | 2010-06-16 | — | — | EP | disclosed |
| US-20080233084-A1 | Interleukin-8 Labelled Via One or More Site Specifically Conjugated Hydrazinonicotinamide (Hynic) Moieties and its Use in Diagnosis of Infection and Inflammation | STICHTING KATHOLIEKE UNIVERSITEIT OF NIJMEGEN (NL) | 2008-09-25 | — | — | US | disclosed |
| US-7402385-B2 | Radiolabeled antibodies for treatment of tumors | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1934251-A2 | INTERLEUKIN-8 LABELLED VIA ONE OR MORE SITE SPECIFICALLY CONJUGATED HYDRAZINONICOTINAMIDE (HYNIC) MOIETIES AND ITS USE IN DIAGNOSIS OF INFECTION AND INFLAMMATION | Stichting Katholieke Universiteit (NL) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042946-A2 | INTERLEUKIN-8 LABELLED VIA ONE OR MORE SITE SPECIFICALLY CONJUGATED HYDRAZINONICOTINAMIDE (HYNIC) MOIETIES AND ITS USE IN DIAGNOSIS OF INFECTION AND INFLAMMATION | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2007-04-19 | — | — | WO | disclosed |
| US-20060039858-A1 | Radiolabeled antibodies and peptides for treatment of tumors | NATIONAL INSTITUTES OF HEALTH | 2006-02-23 | — | — | US | disclosed |
| US-20040156780-A1 | Radiolabeled antibodies for treatment of tumors | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014972-A1 | INFLUENZA VIRUS COMPOSITIONS AND METHODS FOR UNIVERSAL VACCINES | CD81, HAVCR2, CD63 | KMT2A 1459/4885EPHX2 1083/4885HCAR3 4693/4885 |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | KMT2A 3810/4885EPHX2 3454/4885HCAR3 4345/4885 |
| US-11396527-B2 | Dual mass spectrometry-cleavable crosslinking reagents for protein-protein interactions | TIMCC, DCLRE1A, MTCL3 | KMT2A 2994/4885EPHX2 2435/4885HCAR3 3034/4885 |
| US-20180346505-A1 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | HCCS, PNP, NT5C3B | KMT2A 1969/4885EPHX2 2177/4885HCAR3 2864/4885 |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | KMT2A 3810/4885EPHX2 3454/4885HCAR3 4345/4885 |
| US-10752655-B2 | Dual mass spectrometry-cleavable crosslinking reagents for protein-protein interactions | TIMCC, DCLRE1A, MTCL3 | KMT2A 2994/4885EPHX2 2435/4885HCAR3 3034/4885 |
| US-20200354403-A1 | DUAL MASS SPECTOMETRY-CLEAVABLE CROSSLINKING REAGENTS FOR PROTEIN-PROTEIN INTERACTIONS | TIMCC, MTCL3, DCLRE1A | KMT2A 3716/4885EPHX2 3794/4885HCAR3 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.